Cargando…

Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome

BACKGROUND AND PURPOSE: Predictors of response to type-1 hepatorenal syndrome (HRS) therapy are urgently needed. This study's purpose is to evaluate the proposed predictors in these patients. METHODS: Forty-two type-1 HRS patients with cirrhosis were treated with albumin and terlipressin. Clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Razik, Ahmed, Mousa, Nasser, Abdelsalam, Mostafa, Abdelwahab, Ahmed, Tawfik, Mona, Tawfik, Ahmed M., Hasan, Ahmad S., Elhelaly, Rania, El-Wakeel, Niveen, Eldars, Waleed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006449/ https://www.ncbi.nlm.nih.gov/pubmed/32076410 http://dx.doi.org/10.3389/fphar.2020.00009

Ejemplares similares

Helicobacter pylori as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study
por: Abdel-Razik, Ahmed, et al.
Publicado: (2020)

Ascitic Fluid Calprotectin and Serum Procalcitonin as Accurate Diagnostic Markers for Spontaneous Bacterial Peritonitis
por: Abdel-Razik, Ahmed, et al.
Publicado: (2016)

De novo Portal Vein Thrombosis in Non-Cirrhotic Non-Alcoholic Fatty Liver Disease: A 9-Year Prospective Cohort Study
por: Abdel-Razik, Ahmed, et al.
Publicado: (2021)

Advanced Glycation End Products as a Predictor of Diabetes Mellitus in Chronic Hepatitis C-Related Cirrhosis
por: Abdel-Razik, Ahmed, et al.
Publicado: (2020)

De Novo Hepatocellular Carcinoma in Hepatitis C-Related Cirrhosis: Are Advanced Glycation End Products a Key Driver?
por: Abdel-Razik, Ahmed, et al.
Publicado: (2021)

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?
por: Altun, Reskan, et al.
Publicado: (2015)

Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
por: Belcher, Justin M.
Publicado: (2023)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

A risk score to predict 30-day hospital readmission rate in cirrhotic patients with spontaneous bacterial peritonitis
por: Mousa, Nasser, et al.
Publicado: (2023)

Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis
por: Wang, Haiqing, et al.
Publicado: (2018)

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies
por: Sanyal, A. J., et al.
Publicado: (2017)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
por: Kim, Hae Rim, et al.
Publicado: (2013)

Terlipressin-Induced Peripheral Cyanosis in a Patient with Liver Cirrhosis and Hepatorenal Syndrome
por: Chiang, Chi-Wen, et al.
Publicado: (2019)

Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
por: Mohamed, Mohamed M G, et al.
Publicado: (2021)

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
por: Ayyad, Ahlam, et al.
Publicado: (2023)

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2013)

Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
por: Nassar Junior, Antonio Paulo, et al.
Publicado: (2014)

Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
por: Moore, Kevin, et al.
Publicado: (2020)

The Current Management of Hepatorenal Syndrome–Acute Kidney Injury in the United States and the Potential of Terlipressin
por: Flamm, Steven L., et al.
Publicado: (2021)

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure
por: Wong, Florence, et al.
Publicado: (2022)

Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
por: Huang, Xingyue, et al.
Publicado: (2023)

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence
por: Bai, Zhaohui, et al.
Publicado: (2020)

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies
por: Curry, Michael P., et al.
Publicado: (2023)

Terlipressin‐induced foot ischemia
por: Ata, Fateen, et al.
Publicado: (2020)

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial
por: Karvellas, Constantine J., et al.
Publicado: (2023)

Terlipressin-Induced Skin Necrosis While Managing Hepatorenal Syndrome: A Rare Case Report From North India
por: Sudan, Sourav, et al.
Publicado: (2023)

Fanconi syndrome with hepatorenal karyomegaly in a young Sphynx cat
por: Cˇerná, Petra, et al.
Publicado: (2023)

Kidney injury molecule-1: A potential marker of renal recovery after laparoscopic sleeve gastrectomy
por: Khalil, Rania, et al.
Publicado: (2020)

Terlipressin-induced hyponatremic seizure in a child
por: Zaki, Syed Ahmed
Publicado: (2013)

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug
por: Thangaraj, Santhosh Raja, et al.
Publicado: (2023)

Terlipressin or Europressin?
por: Leone, Marc
Publicado: (2009)

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study
por: Kulkarni, Anand V., et al.
Publicado: (2022)

Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis
por: Salerno, Francesco, et al.
Publicado: (2015)

Terlipressin-induced hyponatraemia
por: Gray, R, et al.
Publicado: (2014)

Comparison of Normal Saline, Hypertonic Saline Albumin and Terlipressin plus Hypertonic Saline Albumin in an Infant Animal Model of Hypovolemic Shock
por: Urbano, Javier, et al.
Publicado: (2015)

Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2021)

Metal-based-oxide nanoparticles assisted the in vitro culture growth of Populus alba as micronutrients: essential metabolic processes and genetic stability
por: Ahmed, Mohamed F., et al.
Publicado: (2023)

Eucalyptus Globulus protects against diclofenac sodium induced hepatorenal and testicular toxicity in male rats
por: Mousa, Ahmed Abdelmoniem, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uuh2oh2l60llgejeusbfoo1i5s